Fundz

Gedeon Richter to acquire Mayne Pharma for A$604m

PRIVATENov 17, 2026

Acquiring Company

Gedeon Richter

Acquired Company

Mayne Pharma

HungaryAustraliaBiotechnologyHealth CarePharmaceuticalManufacturingBiotechnologyHealth CarePharmaceutical

Description

Mayne Pharma has agreed to a takeover by Hungarian drugmaker Gedeon Richter at A$6.40 cash per share, valuing its equity at about A$604 million. The offer is 99.4% above Mayne's closing price on 16 November. The deal requires foreign investment and US antitrust approval, shareholder and court approval, and completion of Mayne's sale of its International business to Evaris Pharma. Shareholder voting is expected in late January 2027, with implementation in mid-to-late March 2027.

Quick answer

Gedeon Richter is acquiring Mayne Pharma for $406.8 million, announced November 17, 2026. Gedeon Richter is based in Hungary.

How much did Gedeon Richter pay for Mayne Pharma?
The reported deal value is $406.8 million.
What does Gedeon Richter do?
Gedeon Richter is a Hungarian pharmaceutical company active in women's health, central nervous system and cardiovascular therapeutic areas.
Where are Gedeon Richter and Mayne Pharma based?
Gedeon Richter is based in Hungary. Mayne Pharma is based in Australia.

Source: Fundz verified event record.

Other recent acquisitions in Pharmaceutical and Pharmaceutical

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Gedeon Richter, and when

When Gedeon Richter changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Gedeon Richter raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Gedeon Richter, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Gedeon Richter. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Gedeon Richter

Location

Hungary

About

Gedeon Richter is a Hungarian pharmaceutical company active in women's health, central nervous system and cardiovascular therapeutic areas. It is listed on the Budapest Stock Exchange.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Gedeon Richter makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Gedeon Richter's next move

Learn about Strategic plan

Frequently asked

Who acquired Mayne Pharma?

Mayne Pharma was acquired by Gedeon Richter, based in Hungary. The deal was reported on November 17, 2026. Gedeon Richter is a Hungarian pharmaceutical company active in women's health, central nervous system and cardiovascular therapeutic areas. It is listed on the Budapest Stock Exchange. Gedeon Richter is privately held and operates in Biotechnology.

When did Gedeon Richter acquire Mayne Pharma?

Gedeon Richter's acquisition of Mayne Pharma was reported on November 17, 2026. Mayne Pharma has agreed to a takeover by Hungarian drugmaker Gedeon Richter at A$6.40 cash per share, valuing its equity at about A$604 million. The offer is 99.4% above Mayne's closing price on 16 November. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Mayne Pharma do?

Mayne Pharma is a global specialty pharmaceutical company focused on niche therapeutic areas, including pain management and dermatology. The company is involved in the development and manufacturing of pharmaceuticals. It is privately held, operating in Manufacturing, and is based in Australia.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.